New Study Seeks To Improve Performance of Spinal Muscular Atrophy Type I Clinical Trials

New Study Seeks To Improve Performance of Spinal Muscular Atrophy Type I Clinical Trials
0
(0)

shutterstock_183368201In the study entitled “Observational study of spinal muscular atrophy type I and implications for clinical trials” published in the Neurology journal, the authors describe the clinical features of spinal muscular atrophy type I, data that can be useful to future design of clinical trials.

Spinal muscular atrophy (SMA) is a neurodegenerative disease caused by a genetic mutation in the Smn1 gene (short for spinal motor neuron-1). The lack of SMN1 protein leads to the death of motor neurons and consequently, muscle atrophy. The disease is the leading cause of child death among genetic disorders and currently has no cure. SMA is divided, according to motor function, into four different phenotypes – type I (SMA-I, onset by 6 months), type II (SMA-II, onset 6–18 months), ambulatory type III children, and type IV adults.

In this study, patients with SMA-I were followed at 3 study sites for up to 36 months with registration of clinical features, including serial clinical, motor function, laboratory, and electrophysiologic outcomes. From the 54 eligible patients with SMA-I, 34 patients were enrolled in the study with 50% of them being followed for at least 12 months. The authors found that the median age patients reached the primary endpoint, death, or the necessity for 16 hours of ventilation support per day was 13.5 months. Nutrition support was required previously to ventilation. Patients with symptoms within 3 months of age and after this period, showed no differences on the period reaching the primary endpoint. For SMA-II, gene copy was associated with disease severity, specifically, two copies of Smn2 triggered a higher rate of morbidity and death when compared to 3 copies.

[adrotate group=”3″]

The authors suggest that patients with SMA-I can enroll in longitudinal studies, but this should occur within 8 months after diagnosis, since after this period, a higher risk for feeding support was observed. The patients were available for extensive testing with appropriate resting periods. Additionally, the authors highlight that SMN2 copy number is a predictive biomarker for patients’ stratification. These findings are key, since drug developers have reported significant difficulty in conducting clinical trials with type I SMA. New best practices that would allow for improved participation in clinical trials for SMA Type I therapies.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • biomarkers panel
  • EU approval
  • SRK-015

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Pin It on Pinterest

Share This